Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04555265 |
| Other study ID # |
001kkcng/surg/cuhk |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
September 1, 2020 |
| Est. completion date |
July 31, 2023 |
Study information
| Verified date |
August 2023 |
| Source |
Chinese University of Hong Kong |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with
aggressive tumor behavior. Radiofrequency ablation (RFA) or microwave ablation (MWA) is an
effective curative treatment for early stage HCC. This thermal ablation of liver tumor
induces host immune response with changes in serum concentration of various cytokines. It is
not clear whether this host immune response correlates with tumor recurrence and long-term
patient survival.
Objective: This prospective study is to investigate the change of cytokines' level following
RFA or MWA for HCC and its clinical correlation with tumor recurrence and patients' long-term
survival data.
Hypothesis: Thermal ablation of HCC creates tumor antigen source for the generation of
antitumor immunity and enhances host immune responses. The resulting inflammation and changes
in cytokines may augment tumor cell death by increasing neutrophil infiltration and oxidative
burst mechanisms. On the other hand, there may be negative effects via the production of
growth factors, which could stimulate tumor cell growth within the sub-lethal margin.
Therefore, the ultimate clinical consequences would be significantly affected by these immune
responses.
Study design: This is a prospective study on the measurement of changes of serum cytokines in
patients with HCC undergone RFA or MWA using the commercially available kit (MILLIPEX, Human
cytokine/chemokine magnetic bead panel - Immunology Multiplex Assay ), which measure 10
cytokines, including IL-1β, IL-6, IL-10, IL-12 (p40), IL-12 (p70), TNF-α, CXCL8, CXCL9,
CXCL10, CCL2, CCL5. Statistical correlation will be performed between the cytokine change and
long-term patients' clinical outcome using the prospectively collected database.
Subjects: Patients with HCC undergone RFA or MWA in the Department of Surgery, The Chinese
University of Hong Kong will be recruited. Exclusion criteria were evidence of extrahepatic
metastasis, patients receiving combined hepatectomy and other local ablative therapy and
patients with decompensated liver function that preclude local ablative treatment.
Intervention: RFA or MWA will be performed for patients with HCC. The serum samples of all
consecutive recruited patients will be collected prospectively during the intervention. The
measurement of cytokines level will be performed in the Laboratory of Department of Chemical
Pathology, The Chinese University of Hong Kong under the standard protocol.
Main outcome measures: Primary outcome measure is early intrahepatic tumor recurrence within
one year after thermal ablation. Secondary outcome measures are other tumor recurrence
pattern (late intrahepatic recurrence and extrahepatic metastasis), overall survival and
recurrence-free survival.
Data analysis: All data will be prospectively collected by a research assistant and
computerized in a database. Statistical analysis will be performed by Chi-square test or
Fisher's exact test, where appropriate, to compare discrete variables and Mann-Whitney U test
to compare continuous variables. Cumulative survival will be computed by the Kaplan-Meier
method and compared by Log-rank test. Multivariable analysis using logistic regression model
will be done to identify the independent prognostic factors affecting early tumor recurrence.
Expected results: Understanding the relationship between the cytokines change during thermal
ablation and post-treatment tumor recurrence helps to identify high risk patients for the
possible adjuvant therapy in future study.
Description:
Background Liver cancer is the sixth most common malignancy in the world. It is the fourth
leading cause of cancer-related deaths and has a global incidence of more than 840,000 new
cases in 2018.1 Hepatocellular carcinoma (HCC) accounts for 75% - 85% of primary liver
cancer. Hepatectomy, radiofrequency ablation (RFA) and orthotopic liver transplantation are
the main treatment options for patients with early stage HCC.2 Hepatectomy is only indicated
in patients with early stage HCC and preserved liver function, whereas the application of
liver transplantation is limited globally because of organ shortage. RFA is therefore the
most effective treatment in patients with HCC and borderline liver function due to cirrhotic
liver, especially in Asia-Pacific region where hepatitis B infection is prevalent.
Thermal ablation kills tumors via direct thermal denaturation and coagulation of tumor
proteins.3 The retention of devitalized and damaged tumor cells within the body stimulates a
robust inflammatory response. It has also been reported that thermal ablation creates a tumor
antigen source for the generation of antitumor immunity and enhances host immune responses.4
Activated platelets release interleukin (IL) -1, tumor necrosis factor (TNF), and
transforming growth factor , which increase vascular permeability and promote chemotaxis.
Neutrophils are attracted to the ablation site and perform debris scavenging by releasing
free radicals via oxidative burst mechanisms aimed at destroying inciting agents. Macrophage
migration ensues, transitioning to the proliferative stage, during which macrophages secrete
growth factors, including TNF, vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor.5 The level of proliferative activity of macrophages and lymphocytes is
mediated by IL-6 positively and IL-10 negatively.6, 7 In the event of an incomplete ablation
or nearly complete ablation, viable tumor cells in the sub-lethal ablation zone) may be
affected positively or negatively by the concomitant inflammatory response including
increased levels of cytokines and growth factors. Inflammation following ablation may have
negative effects via the production of growth factors and cytokines by macrophages and
lymphocytes, which could stimulate tumor cell growth within the sub-lethal zone.8 Human and
animal studies using immunohistochemical staining of tissues, enzyme-linked immunosorbent
assay of tissue lysates, and enzyme-linked immunosorbent assay of plasma have shown
significant increase in specific inflammatory and immunomodulatory mediators after RFA.9, 10
The principle investigator has previously reported the inflammatory responses of RFA using
the porcine liver model that the level of systemic inflammatory markers (TNF and IL-1) was
significantly elevated after RFA, when compared with hepatectomy.11 Although pre-clinical
studies on inflammatory responses of thermal ablation for liver tumor are substantial,
clinical correlation of these micro-environmental reaction is limited in the literature.
Erinjeri et al.12 reported that the ablation type and primary diagnosis predicted the change
of IL-6 and patient age predicted the change of IL-10 after thermal ablation of tumors. IL-6
may act as surrogates for immunogenic cell death and the combination of immunogenic
death-inducing procedures with immune check-point inhibitor may be beneficial to prolong
patient survival after RFA.13 At the cellular level, RFA has proven to enhance
tumor-associated antigen-specific T cell response and this contributes to the HCC
recurrence-free survival of patients.14 Nonetheless, it is still not clear about the possible
relationship between RFA-induced cytokines change and its prognostic value on tumor
recurrence and long-term patient survival.
The principle investigator has reported the results of 209 patients receiving RFA as the sole
treatment for HCC.15 The overall tumor recurrence rate was up to 80% with median follow-up of
26 months. Hence, identification of high-risk patients who might develop early recurrence
using surrogate biomarkers (e.g. cytokines) carries an important clinical implication on the
use of adjuvant treatment (e.g. immune check-point inhibitor).
Therefore, the investigators propose this single-center prospective study to analysis the
change in serum cytokines level in patients with HCC treated by RFA or MWA. The result will
be used to correlate the clinical outcome of patients, especially tumor recurrence and
long-term survival outcome. This proposed clinical trial is of clinical importance in
establishing the potential role of immune response as surrogate biomarkers to predict
long-term patient outcome. It establishes the platform for future study of adjuvant treatment
using immune check-point inhibitor for patients with HCC treated by RFA or other thermal
ablative therapy. The investigators' center is a tertiary referral center in Hong Kong
managing patients with complicated hepatobiliary and pancreatic diseases. The number of new
cases of patients with HCC managed in the investigators' center is around 200 every year and
the number of patients with HCC undergoing hepatectomy is around 80 every year. All the
investigators are experts with vast experience in clinical and basic researches of patients
with HCC. The investigators have conducted and published several randomized trials on
management of HCC and other aspects of hepatobiliary surgery in international journals.16-19
Hypothesis RFA or MWA for HCC might induce inflammatory immune response with resulting change
in cytokines level. This micro-environmental reaction might positively or negatively regulate
the residual tumor cells, leading to the significant changes in tumor recurrence and
long-term patient survival.
Aim of study This prospective study aims to investigate the change of cytokines' level
following RFA or MWA for HCC and its clinical correlation with tumor recurrence and patients'
long-term survival data. Primary outcome measure is early tumor recurrence within one year
after RFA. Secondary outcome measures are other tumor recurrence pattern (late intrahepatic
recurrence and extrahepatic metastasis), overall survival and recurrence-free survival.
Primary outcome measure is early intrahepatic tumor recurrence within one year after RFA and
MWA. Secondary outcome measures are other tumor recurrence pattern (late intrahepatic
recurrence and extrahepatic metastasis), overall survival and recurrence-free survival.
Analysis of cytokines level using studied patient serum samples
Analytes available:
IL-1β, IL-6, IL-10, IL-12 (p40), IL-12 (p70), TNF-α, CXCL8, CXCL9, CXCL10, CCL2, CCL5
Commercially available kit:
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel - Immunology Multiplex Assay
Application of kit:
Simultaneously analyze multiple cytokine and chemokine biomarkers with MILLIPLEX MAP Human
Cytokine/Chemokine Magnetic Bead Panel - Immunology Multiplex Assay, in human serum, plasma
and cell culture samples. This is an overnight incubation assay.
Expected time of study The investigators' institution is a major tertiary referral center for
HCC in Hong Kong. The patient recruitment will be started once the approval from Institution
Review Board is obtained. The recruitment period is around 12 months to 18 months. With the
median follow-up period of around 18 months, It is expected that the total period of study is
three years.
Sample size estimation Expected number of patients to be recruited is estimated at 60
according to the past patient number undergoing treatment under the department.
Statistical analysis All data will be prospectively collected by a research assistant and
computerized in a database. Statistical analysis will be performed by Chi-square test or
Fisher's exact test, where appropriate, to compare discrete variables and Mann-Whitney U test
to compare continuous variables. Cumulative survival will be computed by the Kaplan-Meier
method and compared by Log-rank test. Multivariable analysis using logistic regression model
will be done to identify the independent prognostic factors affecting early tumor recurrence.
Ethical Consideration This study will be carried out in accordance with the Declaration of
Helsinki of the World Medical Association and the International Conference on Harmonization -
Good Clinical Practice.
Consent Written voluntary consent will be obtained after full explanation of the trial to the
patient before operation and randomization.
Relevance to clinical applications
This study carries significant clinical influence on the surgical management of patient with
HCC. Since hepatitis B infection is still endemic in Asia-Pacific area like Hong Kong,
hepatitis B related HCC is still a burden among the whole pool of cancer patients. This study
aims to establish the potential role of immune response as surrogate biomarkers to predict
long-term patient outcome. It enhances the development of the platform for future study of
adjuvant treatment using immune check-point inhibitor for patients with HCC treated by
thermal ablative therapy.
